DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Third Quarter Performance Report
June 9, 2021

Released for the
2020-21 Fiscal Year Continue reading


CDC Call Regarding Johnson & Johnson’s Janssen COVID-19 Vaccine
April 15, 2021

The CDC Clinician Outreach and Communication Activity (COCA) will be hosting a call at 2:00 PM ET regarding CVST associated with the Johnson & Johnson Janssen COVID-19 vaccine Continue reading




Supporting Documents

Medical Degree Verification
NICA FORM
Postgraduate Training Verification
License Verification

Supporting Documents - Visiting Physician

NICA FORM